Compare
AVITA Medical, Inc. vs Sight Sciences, Inc. vs PRO DEX Inc vs Meihua International Medical Technologies Co., Ltd.
| Latest fiscal year | AVITA Medical, Inc. RCEL | Sight Sciences, Inc. SGHT | PRO DEX Inc PDEX | Meihua International Medical Technologies Co., Ltd. MHUAF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $71.61M | $77.36M | $77.55M | $61.79M |
| Revenue growth (YoY) | +11.5% | -3.1% | +16.5% | -36.2% |
| Gross margin | 82.1% | 86.2% | 31.4% | 31.0% |
| Operating margin | -59.4% | -48.0% | 16.8% | 13.4% |
| Net margin | -67.8% | -49.7% | 17.6% | 11.0% |
| Net income | -$48.59M | -$38.43M | $13.66M | $6.78M |
| EPS (Diluted) | -$1.74 | -$0.74 | $4.12 | $18.04 |
| Operating cash flow | -$31.20M | -$29.69M | $7.24M | $569.9K |
| Free cash flow | -$32.20M | -$29.92M | $6.76M | $554.3K |
| Cash & equivalents | $10.24M | $91.97M | $8.19M | n/a |
| Total assets | $56.39M | $115.30M | $74.51M | $207.18M |
| Total liabilities | $73.04M | $51.36M | $26.88M | n/a |
| Shareholders' equity | -$16.65M | $63.94M | $47.63M | $188.93M |
| Return on year-end equity | n/a | -60.1% | 28.7% | 3.6% |
| Shares outstanding | 30.57M | 53.49M | 3.19M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | AVITA Medical, Inc. | Sight Sciences, Inc. | PRO DEX Inc | Meihua International Medical Technologies Co., Ltd. |
|---|---|---|---|---|
| Latest | $71.61M Ended 2025-12-31 | $77.36M Ended 2025-12-31 | $77.55M Ended 2026-06-30 | $61.79M Ended 2025-12-31 |
| 1 year earlier | $64.25M Ended 2024-12-31 | $79.87M Ended 2024-12-31 | $66.59M Ended 2025-06-30 | $96.91M Ended 2024-12-31 |
| 2 years earlier | $50.14M Ended 2023-12-31 | $81.06M Ended 2023-12-31 | $53.84M Ended 2024-06-30 | $97.10M Ended 2023-12-31 |
| 3 years earlier | $34.42M Ended 2022-12-31 | $71.33M Ended 2022-12-31 | $46.09M Ended 2023-06-30 | $103.35M Ended 2022-12-31 |
| 4 years earlier | n/a | $48.96M Ended 2021-12-31 | $42.04M Ended 2022-06-30 | $104.04M Ended 2021-12-31 |